By controlling dangerous inflammation, CytoSorb® is enabling
superior outcomes in critically-ill patients, with reduced overall
costs of intensive care in its sights
LONDON, Aug. 2, 2017 /PRNewswire/ -- Based on its
recent analysis of the blood purification market, Frost &
Sullivan recognizes CytoSorbents Corporation with the 2017 Global
Frost & Sullivan Award for Product Leadership. CytoSorbents'
deceptively simple yet powerful blood purification therapy,
CytoSorb®, helps critical care physicians and heart
surgeons control deadly inflammation in their patients.
CytoSorb® actively reduces circulating cytokines,
toxins, and other substances in blood that feed and perpetuate
uncontrolled inflammation in a diverse set of medical emergencies
such as sepsis, infection, trauma, cardiac surgery, and liver
failure. Its ultimate aim is to prevent a patient from being killed
by his or her own out-of-control immune response.
Logo -
http://mma.prnewswire.com/media/541276/Frost_and_Sullivan_Cytosorbents_Award_Logo.jpg
"There were many factors that led to our selection of
CytoSorb® for this year's Global Product Leadership
Award," said Frost & Sullivan Research Analyst Aish Vivek. "Among the most important was the
recognition that this innovative product is surprisingly
well-positioned to help solve two long-standing, difficult, and
tightly linked fundamental problems with hospital medicine today.
These include the high rates of death from common critical
illnesses such as sepsis that have no approved treatment, and the
resulting staggering costs and losses in critical care that are
financially crippling hospital networks and healthcare systems
throughout the world."
"Further strengthening CytoSorb's position is the scarcity of
viable competition in the lucrative and vast global critical care
and cardiac surgery markets, the strong physician usage and revenue
growth, and the external validation from well-respected industry
partners, such as Fresenius Medical Care and Terumo Cardiovascular,
and government funding agencies. As a high margin, single-use
product that works with existing blood pumps in hospitals,
CytoSorb® also has an attractive business model that is
expected to drive early and significant profitability of the
company."
"CytoSorb® has taken blood purification as a means to
control inflammation to the next level, with its patented blood
compatible, porous polymer bead technology," concluded Aish Vivek. "This best-of-breed solution is
approved in the European Union and has been used in more than
23,000 treatments to help save many lives across 44 countries.
As the clinical experience and scientific publications
continue to grow, we predict that CytoSorbents, through
CytoSorb®, will solidify its leadership in critical care
and cardiac surgery, with expansion into other promising fields
such as cancer immunotherapy, and treatment of chronic illness. We
are also excited to follow along as CytoSorbents initiates a
registration trial later this year that targets U.S. FDA
approval."
Overall, for positioning itself strongly with its
CytoSorb® therapy and serving a wide array of
applications, Frost & Sullivan is pleased to present
CytoSorbents with the 2017 Global Frost & Sullivan Award for
Product Leadership in the blood purification market.
Each year, Frost & Sullivan presents this award to the
company that has developed a product with innovative features and
functionality, gaining rapid acceptance in the market. The award
recognizes the quality of the solution and the customer value
enhancements it enables.
Frost & Sullivan Best Practices Awards recognize companies
in a variety of regional and global markets for demonstrating
outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and
strategic product development. Industry analysts compare market
participants and measure performance through in-depth interviews,
analysis, and extensive secondary research to identify best
practices in the industry.
About CytoSorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO) is a leader in
critical care immunotherapy, specializing in blood purification.
Its flagship product, CytoSorb®, is approved in the
European Union with distribution in 44 countries worldwide, as a
safe and effective extracorporeal cytokine adsorber, designed to
reduce the "cytokine storm" or "cytokine release syndrome" that
could otherwise cause massive inflammation, organ failure and death
in common critical illnesses such as sepsis, burn injury, trauma,
lung injury, complications of surgery, cancer immunotherapy, and
pancreatitis. These are conditions where the risk of death is
extremely high, yet no effective treatments exist.
CytoSorb® is also being used during and after cardiac
surgery to remove inflammatory mediators, such as cytokines and
free hemoglobin, which can lead to post-operative complications,
including multiple organ failure. In 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 23,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $19
million from DARPA, the U.S. Army, the U.S. Department of
Health and Human Services, the National Institutes of Health (NIH),
National Heart, Lung, and Blood Institute (NHLBI), U.S. Special
Operations Command (SOCOM) and others. The Company has numerous
products under development based upon this unique blood
purification technology, protected by 32 issued U.S. patents,
multiple international patents, and many applications pending
worldwide. Products under development include CytoSorb-XL™,
HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.
Visit www.cytosorbents.com and www.cytosorb.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants. For more than
50 years, we have been developing growth strategies for the global
1000, emerging businesses, the public sector, and the investment
community. Contact us: Start the discussion.
Contact:
Aish Vivekanandan
Phone: 210-477-8495
Email: aish.vivekanadan@frost.com